The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1467-1472.e1 , June 2008

Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa

Received 27 June 2007 ,Revised 10 March 2008 ,Accepted 18 March 2008.

  • Image Result

    Immunofluorescence staining of tonsillar sections and nasal sections from GP-IT–treated patients. A, Foxp3+CD4+ cells in the tonsil (inset shows control after preadsorption with human Foxp3 peptide, m

    Immunofluorescence staining of tonsillar sections and nasal sections from GP-IT–treated patients. A, Foxp3+CD4+ cells in the tonsil (inset shows control after preadsorption with human Foxp3 peptide, magnification ×200). B, Foxp3+CD4+ cells in the nose (magnification ×400). C, CD3+CD25+Foxp3+ cells in the tonsil (magnification ×200). D, Foxp3+CD3+CD25+ cells in the nose (magnification ×400). E and F, Foxp3+CD3+IL-10+ cells in the nose (magnification ×1000). G, Percentage of Foxp3+ cells that were CD3+, IL-10+, or CD3+IL-10+.

  • Image Result
    Foxp3+ (A), Foxp3+CD25+ (B), and Foxp3+CD4+ (C) cells in patients with hay fever, GP-IT–treated patients, and nonatopic control subjects. Statistical analysis was performed by using the Mann-Whitney U

    Foxp3+ (A), Foxp3+CD25+ (B), and Foxp3+CD4+ (C) cells in patients with hay fever, GP-IT–treated patients, and nonatopic control subjects. Statistical analysis was performed by using the Mann-Whitney U test.

 Funding for this project was from the Medical Research Council UK. K.T.N.-A. was supported by the Advanced Drug Discovery Initiative, a collaborative project between Imperial College Trust and GlaxoSmithKline. ALK-Abelló, Hørsholm, Denmark, supported the clinical trial of grass pollen subcutaneous immunotherapy.

 Disclosure of potential conflict of interest: S. R. Durham has consulting arrangements with ALK-Abelló; has received research support from ALK-Abelló; is partially funded by the Immune Tolerance Network of the National Institutes of Health; and is on the speakers' bureau for ALK-Abelló, Allergy Therapeutics, and Stallergenes. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00597-6

doi: 10.1016/j.jaci.2008.03.013

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1467-1472.e1 , June 2008

Article Tools

* Image Usage & Resolution